Interestingly, TGFβ resistance has been shown to be linked to epigenetic silencing of the expression of the TGFβ receptor, which can be partially reversed with demethylating agent therapy (thus resensitising tumour cells to the pro-apoptotic effect of TGFβ) (Chen et al., 2007). The gene discussed is TGFB1; the disease is neoplasm.